Participants treated with liraglutide (239), semaglutide (240), or tirzepatide (200) in the clinical trials had a percent reduction in fat mass approximately three times greater than the reduction in lean mass, leading to an overall improvement in body composition
Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease
Corinne to discuss a personalized approach to weight loss that addresses the complete picture of your health
In my experience, GLP-1 agonists have shown remarkable anti-inflammatory effects
We carefully select premium protein sources like fish (including salmon), chicken, beef, pork, and lamb to support both taste and nutrition
This five-year demonstration would waive the coverage exclusion for these drugs to increase access to GLP-1 medications